037 Treating secondary progressive multiple sclerosis in the UK: use of guidelines and stopping criteria

Le résumé fourni par la source

Background As new treatment approaches emerge for progressive forms of multiple sclerosis (MS), it is important to understand the factors underlying current practice. Methods We used a structured questionnaire to interview 59 healthcare professionals (HCPs) from geo- graphically-dispersed UK MS centres about current disease modifying therapy (DMT) management of patients with suspected/confirmed secondary progressive MS (SPMS). Results Of 43 HCPs (73%) who follow guidelines for DMT management of patients transitioning from relapsing-remitting multiple sclerosis (RRMS) to SPMS, most (n=37/43, 86%) use the NHS England (NHSE) algorithm; 7/43 (16%) use ABN guidance. Fifty-eight (98%) HCPs use DMTs to treat patients with RRMS whom they suspect may be transitioning to SPMS and 30 (51%) for (a minority of) patients with newly- diagnosed SPMS. Expanded Disability Status Scale (EDSS) 7.0 was the most frequently-reported criterion used for stopping DMTs (n=29, 49%), however, a variety of other criteria were used and a small majority of HCPs reported continuing DMTs beyond EDSS 7.0 in certain circumstances (most commonly recent relapse activity [n=32, 54%] or in younger patients [n=20, 34%]). Conclusions Although most HCPs follow NHSE guidelines, a range of DMT stopping criteria are employed in clinical practice and treatment decisions may be based on individual patient circumstances. katherine.rhys@novartis.com

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.